Axsome Therapeutics, Inc.

États‑Unis d’Amérique


Commandez votre montre hebdomadaire Axsome Therapeutics, Inc.
Quantité totale PI 270
Rang # Quantité totale PI 4 894
Note d'activité PI 3,2/5.0    262
Rang # Activité PI 2 660
Symbole boursier
ISIN US05464T1043
Capitalisation 4,900M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

164 25
13 18
30 13
7
 
Dernier brevet 2025 - Pharmaceutical compositions comp...
Premier brevet 2014 - Therapeutic compositions compris...
Dernière marque 2025 - MORPHEUS (DESIGN)
Première marque 2015 - AXSOME

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics,...
P/S Providing a website featuring information on managing behavioral symptoms associated with Alzheim...
P/S Management of pharmacy benefit programs featuring a medical benefit co-pay card; Financial admini...
P/S Medicated and pharmaceutical preparations for the treatment and prevention of migraines; medicate...
P/S Prescription medicated and pharmaceutical preparations for the treatment and prevention of migrai...
Invention Pharmaceutical compositions comprising meloxicam. Disclosed herein are compositions comprising a...
P/S Medicated and pharmaceutical preparations for use in connection with humans, namely, those for th...
P/S Promoting public awareness of migraines; providing business management of pharmacy benefit progra...
Invention Compounds and combinations thereof for treating neurological and psychiatric conditions. Describ...
Invention Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder....
Invention Use of esreboxetine to treat nervous system disorders. Described herein are methods of treating f...
Invention Use of reboxetine to treat narcolepsy. Described herein are methods of treating narcolepsy with ...
2024 Invention Microparticles containing bupropion. This disclosure relates to microparticles containing buprop...
Invention Pharmaceutical compositions comprising bupropion and cysteine. This disclosure relates to pharma...
Invention Compounds and combinations thereof for treating depression in patients. This disclosure relates t...
Invention Pharmaceutical compositions comprising meloxicam. Disclosed herein is a method of treating migra...
Invention Pharmaceutical compositions comprising bupropion and cysteine. This disclosure relates to pharmac...
Invention Pharmaceutical compositions comprising meloxicam. max of meloxicam of 3 hours or less.
Invention Solriamfetol for improving cognitive health in apnea patients. Disclosed herein are methods of im...
Invention Pharmaceutical compositions comprising meloxicam. maxmax of meloxicam of 3 hours or less.
Invention Pharmaceutical compositions comprising meloxicam. Disclosed herein is a method of treating migrai...
Invention Dosage forms and methods for enantiomerically enriched or pure bupropion. This disclosure relate...
Invention Use of solriamfetol for the treatment of orphan diseases. The present invention relates to a meth...
P/S Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics...
Invention Methods of administering solriamfetol to lactating women. Provided herein according to some embod...
Invention Solriamfetol for the treatment of certain neurological conditions. Disclosed herein are methods o...
Invention Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated wi...
Invention Pharmaceutical compositions comprising a tolfenamic acid. max of meloxicam of 3 hours or less.
P/S Downloadable cloud-based software for the purpose of tracking, managing and storing information r...
P/S Downloadable cloud-based software for the purpose of tracking, managing and storing information ...
P/S Promoting public awareness of migraines Medicated and pharmaceutical preparations for use in conn...
P/S Promoting public awareness of migraines Printed educational materials in the field of migraines P...
Invention Compositions for delivery of reboxetine. Described herein are methods for the administration of ...
Invention Combination dosage forms and administration thereof. This disclosure relates to methods of admin...
P/S Prescription medicines for the treatment of Fibromyalgia.
P/S Prescription medicines for the treatment of Fibromyalgia.
2023 Invention Use of reboxetine to treat narcolepsy. Described herein are methods of treating narcolepsy with c...
Invention Use of mazindol to treat nervous system disorders. Described herein are methods of treating narco...
Invention Compounds and combinations thereof for treating neurological and psychiatric conditions. Describe...
P/S Prescription medicines for the treatment of Fibromyalgia
P/S house mark for medicated and pharmaceutical preparations for use in connection with humans, namel...
P/S Management of pharmacy benefit programs featuring a medical benefit co-pay card; financial admini...
P/S Management of pharmacy benefit programs featuring a medical benefit co-pay card (term considered...
Invention Methods of modulating tetrabenazine metabolites plasma levels using bupropion. This disclosure r...
2022 Invention Methods and compisitions for ameliorating biomarkers associated with cardiovascualr risk using (r...
2021 P/S Prescription medicines for the treatment of migraines.
P/S Prescription medicines for the treatment of migraines.
P/S Consulting services in the field of health, namely pharmaceutical consultancy services; providing...
P/S Education services, namely, providing classes, seminars, conferences and workshops in the field ...
P/S Providing an on-line forum for patients and doctors to communicate and discuss depression and tre...
P/S Providing an on-line forum for patients and doctors to communicate and discuss depression and tr...
P/S Pharmaceutical preparations, namely, prescription medicines for the treatment of depression.